Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
01/10/2020 | 12:15pm EST

NEW YORK, Jan. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Dermira, Inc. (NASDAQ: DERM) and its board of directors concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Stockholders will receive $18.75 per share of Dermira, Inc. common stock that they hold. The transaction is valued at approximately $1.1 billion and is expected to close in the first quarter of 2020.

If you are a stockholder of Dermira, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/derm. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).  

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.  

Attorney Advertising. Prior results do not guarantee a similar outcome.

Cision
View original content:http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-dermira-inc-300985030.html

SOURCE Rowley Law PLLC


© PRNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND COMPANY
02/24ELI LILLY AND : Lilly to Participate in Cowen Health Care Conference
AQ
02/24ELI LILLY AND : Lilly To Participate in SVB Leerink Global Healthcare Conference
AQ
02/24ELI LILLY AND : Trulicity is the first and only type 2 diabetes medicine approve..
AQ
02/21ELI LILLY AND : Trulicity® (dulaglutide) is the first and only type 2 diabetes m..
PR
02/21ELI LILLY AND : Lilly to Participate in Cowen Health Care Conference
PR
02/21ELI LILLY AND : Lilly To Participate in SVB Leerink Global Healthcare Conference
PR
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
RE
02/19ELI LILLY AND : & CO Management's Discussion and Analysis of Results of Operatio..
AQ
02/19ELI LILLY AND : Backed Terns Reports Positive Phase 1 Results for TERN-101 in NA..
DJ
More news